Market Access What the low impact of Humira biosimilars teaches us about d... Almost everyone seems to agree that drug prices are too high.
News ASH: Gilead preps filing for anito-cel on iMMagine-1 data Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
